Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres
- PMID: 26338177
- PMCID: PMC4731431
- DOI: 10.1007/s00259-015-3157-8
Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres
Abstract
Radioembolization with (90)Y-loaded microspheres is increasingly used in the treatment of primary and secondary liver cancer. Technetium-99 m macroaggregated albumin (MAA) scintigraphy is used as a surrogate of microsphere distribution to assess lung or digestive shunting prior to therapy, based on tumoral targeting and dosimetry. To date, this has been the sole pre-therapeutic tool available for such evaluation. Several dosimetric approaches have been described using both glass and resin microspheres in hepatocellular carcinoma (HCC) and liver metastasis. Given that each product offers different specific activities and numbers of spheres injected, their radiobiological properties are believed to lightly differ. This paper summarizes and discusses the available studies focused on MAA-based dosimetry, particularly concentrating on potential confounding factors like clinical context, tumor size, cirrhosis, previous or concomitant therapy, and product used. In terms of the impact of tumoral dose in HCC, the results were concordant and a response relationship and tumoral threshold dose was clearly identified, especially in studies using glass microspheres. Tumoral dose has also been found to influence survival. The concept of treatment intensification has recently been introduced, yet despite several studies publishing interesting findings on the tumor dose-metastasis relationship, no consensus has been reached, and further clarification is thus required. Nor has the maximal tolerated dose to the liver been well documented, requiring more accurate evaluation. Lung dose was well described, despite recently identified factors influencing its evaluation, requiring further assessment. Conclusion: MAA SPECT/CT dosimetry is accurate in HCC and can now be used in order to achieve a fully customized approach, including treatment intensification. Yet further studies are warranted for the metastasis setting and evaluating the maximal tolerated liver dose.
Keywords: Predictive dosimetry; Prognosis; Selective internal radiation therapy.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4731431/bin/259_2015_3157_Fig1_HTML.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4731431/bin/259_2015_3157_Fig2_HTML.gif)
Similar articles
-
Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.J Nucl Med. 2012 Feb;53(2):255-63. doi: 10.2967/jnumed.111.094235. J Nucl Med. 2012. PMID: 22302962
-
Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres.Nucl Med Commun. 2015 Apr;36(4):340-9. doi: 10.1097/MNM.0000000000000257. Nucl Med Commun. 2015. PMID: 25563137
-
A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.J Vasc Interv Radiol. 2014 Feb;25(2):277-87. doi: 10.1016/j.jvir.2013.11.007. J Vasc Interv Radiol. 2014. PMID: 24461133
-
90Y-Loaded Microsphere SIRT of HCC Patients With Portal Vein Thrombosis: High Clinical Impact of 99mTc-MAA SPECT/CT-Based Dosimetry.Semin Nucl Med. 2019 May;49(3):218-226. doi: 10.1053/j.semnuclmed.2019.01.006. Epub 2019 Feb 7. Semin Nucl Med. 2019. PMID: 30954188 Review.
-
Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan.Q J Nucl Med Mol Imaging. 2011 Apr;55(2):168-97. Q J Nucl Med Mol Imaging. 2011. PMID: 21386789 Review.
Cited by
-
Use of dose-volume histograms for metabolic response prediction in hepatocellular carcinoma patients undergoing transarterial radioembolization with Y-90 resin microspheres.Ann Nucl Med. 2024 Jul;38(7):525-533. doi: 10.1007/s12149-024-01926-4. Epub 2024 Apr 22. Ann Nucl Med. 2024. PMID: 38647875
-
MIRD Pamphlet No. 29: MIRDy90-A 90Y Research Microsphere Dosimetry Tool.J Nucl Med. 2024 Feb 22;65(5):794-802. doi: 10.2967/jnumed.123.266743. Online ahead of print. J Nucl Med. 2024. PMID: 38388514
-
Intraprocedural C-arm dual-phase cone-beam enhancement patterns correlate with tumor absorbed dose after radioembolization.Med Phys. 2024 Apr;51(4):3045-3052. doi: 10.1002/mp.16882. Epub 2023 Dec 8. Med Phys. 2024. PMID: 38064591
-
Predictive Value of [99mTc]-MAA-Based Dosimetry in Hepatocellular Carcinoma Patients Treated with [90Y]-TARE: A Single-Center Experience.Diagnostics (Basel). 2023 Jul 20;13(14):2432. doi: 10.3390/diagnostics13142432. Diagnostics (Basel). 2023. PMID: 37510175 Free PMC article.
-
Clinical impact of 99mTc-MAA SPECT/CT-based personalized predictive dosimetry in selective internal radiotherapy: a real-life single-center experience in unresectable HCC patients.Eur J Hybrid Imaging. 2023 Jul 7;7(1):12. doi: 10.1186/s41824-023-00171-8. Eur J Hybrid Imaging. 2023. PMID: 37414964 Free PMC article.
References
-
- Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Jaarke Vannoote J, et al. Phase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or With Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy. J Clin Oncol. 2010;28(23):3687–94. doi: 10.1200/JCO.2010.28.5643. - DOI - PubMed
-
- Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY). Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54(3):868–78. doi: 10.1002/hep.24451. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical